| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
Concentrated thioridazine (0.01-100 μM; 48 h) treatment decreases NCI-N87 and AGS cell viability [2]. Thioridazine (1-15 μM; 24-48 h) promotes cell death via the mitochondrial pathway and pharyngeal pathways. Thioridazine (15 μM; 24 h) lowers cervical (HeLa, Caski, and C33A) and endometrial [2]. Cancer cell viability (HEC-1-A and KLE) [4]. ;24 h) By interfering with PI3K/Akt, it causes cervical cancer cells to develop in the G1 cell cycle [4]. Development of conjugated Bowman immotile cell lines that are susceptible to thioridazine inhibitors [3].
|
|---|---|
| ln Vivo |
Thioridazine (25 mg/kg; intraperitoneal injection every three days for three weeks) can decrease the amount of pluripotent cell carcinoma (EC) cells within the tumor and increase the survival time of tumor-bearing animals [5].
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: NCI-N87 and AGS Cell Tested Concentrations: 0.01, 0.1, 0.5, 1, 5, 10, 20, 50, 100 μM Incubation Duration: 48 hrs (hours) Experimental Results: demonstrated cytotoxicity in gastric cancer cells . Western Blot Analysis [1] Cell Types: NCI-N87 and AGS cells Tested Concentrations: 1, 5, 10, 15 μM Incubation Duration: 24, 48 hrs (hours) Experimental Results: Downregulation of caspase-9, caspase-8 and caspase-3 precursors. |
| Animal Protocol |
Animal/Disease Models: Nude mice and Rag2KO mice were injected with iPS cells or NT2D1 cells [5]
Doses: 25 mg/kg Administration Doses: 5.0 mg/kg; subcutaneous injection) to reduce oral behavior and selectively prevent repetitive head bobbing [1]. Route of Administration: intraperitoneal (ip) injection every 3 days for 3 weeks. Experimental Results: diminished the number of OCT4-expressing cells in malignant teratocarcinoma and prolonged the survival of tumor-bearing mice. Has no effect on fertility. |
| References |
[1]. Tschanz JT, et, al. Atypical antipsychotic drugs block selective components of amphetamine-induced stereotypy. Pharmacol Biochem Behav. 1988 Nov;31(3):519-22.
[2]. Mu J, et, al. Thioridazine, an antipsychotic drug, elicits potent antitumor effects in gastric cancer. Oncol Rep. 2014 May;31(5):2107-14. [3]. Aguilar-Vega L, et, al. Antibacterial properties of phenothiazine derivatives against multidrug-resistant Acinetobacter baumannii strains. J Appl Microbiol. 2021 Apr 22. [4]. Kang S, et, al. Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells. Apoptosis. 2012 Sep;17(9):989-97. [5]. Loehr AR, et, al. Targeting Cancer Stem Cells with Differentiation Agents as an Alternative to Genotoxic Chemotherapy for the Treatment of Malignant Testicular Germ Cell Tumors. Cancers (Basel). 2021 Apr 23;13(9):2045. |
| Molecular Formula |
C21H26N2S2.HCL
|
|---|---|
| Molecular Weight |
407.03
|
| CAS # |
130-61-0
|
| Related CAS # |
Thioridazine;50-52-2
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
CSC(C=C1N2CCC3N(C)CCCC3)=CC=C1SC4=C2C=CC=C4.[H]Cl
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~245.68 mM)
DMSO : ≥ 45 mg/mL (~110.55 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.11 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.11 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.11 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 12.5 mg/mL (30.71 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4568 mL | 12.2841 mL | 24.5682 mL | |
| 5 mM | 0.4914 mL | 2.4568 mL | 4.9136 mL | |
| 10 mM | 0.2457 mL | 1.2284 mL | 2.4568 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
